From molecules to the mind — a structured learning resource for neurology mastery
Comprehensive · Visual · Interactive
Lobes, sulci, gyri, meninges, ventricular system.
Circle of Willis, ACA/MCA/PCA, stroke territories.
Midbrain, pons, medulla; cranial nerve nuclei.
Deep nuclei, peduncles, pathways, ataxia patterns.
Hippocampus, amygdala, Papez circuit, memory.
CN I-XII, foramina, nuclei, clinical testing.
Direct/indirect pathways, PD/Huntington, DBS targets.
Na+/K+ channels, Hodgkin-Huxley, propagation.
Neurotransmitters, vesicles, receptors, Ex/Inhibitory.
Mental status, cranial nerves, motor, sensory, reflexes, coordination.
UMNL vs LMNL, topographic syndromes, "where is the lesion?"
Approach to common presentations, red flags, categories.
Focal vs generalized, 2025 updates, absence vs FIA, lateralizing signs.
ILAE 2005/2014, three diagnostic criteria, provoked vs unprovoked.
ILAE 2017 three-level, four epilepsy types, six etiologies, 34 syndromes.
JME, JAE, GTCA, GEFS+, SUDEP, ASM withdrawal.
CAE, SeLECTS, SeLEAS, Dravet, LGS, FIRES, ILAE 2022 MAE criteria.
ASM mechanisms, PK/PD, drug selection, TDM, DRE, interactions.
10-20 system, normal rhythms, epileptiform, activation, NCSE criteria.
SCN1A-Dravet, KCNQ2, CDKL5, PCDH19, mTOR pathway, TSC, GLUT1.
3T epilepsy MRI protocol, HS, FCD, DNET, ganglioglioma, PET, SISCOM.
VPA 6-10% MCM, NEAD IQ deficit, LTG/LEV preferred, PK changes, NICE NG217.
MDS 2015 clinical diagnostic criteria, red flags, supportive criteria.
D1/D5 agonist for PD. ICD risk 1.2% vs 17-28% with D2/D3 agonists.
TOR1A/DYT1, GCH1-DRD, BoNT mechanism, GPi-DBS, EARLYSTIM trial.
Hereditary cSVD: NOTCH3, HTRA1, CTSA, GOM, temporal pole MRI.
Prophylaxis comparison, Cephalalgia 2026, 70% vs 33% continuation.
Stroke, Neuromuscular, Dementia, CNS Infection, Sleep, MS/NMOSD — PDFs ready for ingestion
Source
Tap each card to reveal the answer
Tap each question to reveal the answer